Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria

Antiviral Therapy

Volumn 10, Issue SUPPL. 2, 2005, Pages

  Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; CONFERENCE PAPER; DIABETES MELLITUS; DOSE RESPONSE; FATTY LIVER; GENOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPOGONADISM; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MYOPATHY; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TUBULAR DYSFUNCTION;

ANTI-HIV AGENTS; DNA, MITOCHONDRIAL; HIV INFECTIONS; HUMANS; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 24044496608     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Martin JL, Brown CE, Matthews-Davis N & Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrobial Agents & Chemotherapy 1994; 38:2743-2749.
2. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ & Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-723.
3. Brinkman K, Hofsted HJ, Burger DM, Smeitink JAM & Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
4. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ & Delfraissy JF. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089.
5. Delfraissy JF, Blanche S, Tardieu M, Barret B, Rustin P & Mayaux MJ. Mitochondrial and mitochondrial-like symptoms in children born to HIV-infected mothers. Exhaustive evaluation in a large prospective cohort. 8th Conference on Retroviruses & Opportunistic Infections. 1-4 February 2001, Chicago, IL, USA. Abstract 625B.
6. McIntosh K. Toxicity of perinatally administered zidovudine. 7th Conference on Retroviruses & Opportunistic Infections. 30 January-2 February 2000, San Francisco, CA, USA. Abstract S14.
7. Noguera A, Fortuny C, Munoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, Pou J & Jimenez R. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114:e598-e603.
8. Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, De Rossi A, Sturkenboom M & D'Elia R. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15:1074-1075.
9. Poirier MC, Olivero OA, Walker DM & Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicology & Applied Pharmacology 2004; 199:151-161.
10. Lombes A, Bonilla E & Dimauro S. Mitochondrial encephalomyopathies. Revista de Neurologia 1989; 145:671-689.
11. Fromenty B & Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Journal of Hepatology 1997; 26(Suppl 2):43-53.
12. Treem WR & Sokol RJ. Disorders of the mitochondria. Seminars in Liver Disease 1998; 18:237-253.
13. Taylor RW, Chinnery PF, Clark KM, Lightowlers RN & Turnbull DM. Treatment of mitochondrial disease. Journal of Bioenergetics & Biomembranes 1997; 29:195-205.
14. Chinnery PF, Howell N, Andrews RM & Turnbull DM. Clinical mitochondrial genetics. Journal of Medical Genetics 1999; 36:425-436.
15. Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, Roullet E & Gherardi R. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Annals of Neurology 1991; 29:606-614.
16. Modica Napolitano JS. AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochemical & Biophysical Research Communications 1993; 194:170-177.
17. Barile M, Valenti D, Hobbs GA, Abruzzese MF, Keilbaugh SA, Passarella S, Quagliariello E & Simpson MV. Mechanisms of toxicity of 3′-azido- 3′-deoxythymidine: its interaction with adenylate kinase. Biochemical Pharmacology 1994; 48:1405-1412.
18. Valenti D, Barile M & Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. International Journal of Molecular Medicine 2000; 6:93-96.
19. Pan Zhou XR, Cui L, Zhou XJ, Sommadossi JP & Darley Usmar VM. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrobial Agents & Chemotherapy 2000; 44:496-503.
20. Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV & Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 2002; 346:811-820.
21. McComsey G, Tan DJ, Lederman M, Wilson E & Wong LJ. Analysis of mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with of without lipoatrophy. AIDS 2002; 16:513-518.
22. Morgello S, Wolfe D, Gadfrey E, Feinstein R, Tagliati M & Simpson DM. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy. Acta Neuropathologica 1995; 90:366-374.
23. Shikuma CM, Hu N, Yost F, Waslien C, Shimizu S & Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-1809.
24. Gallant J, Staszewski S, Pozniak A, Lu B, Miller MD, Coakley DF & Cheng A. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naïve patients: a 48 week interim analysis. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. 27-30 September 2002, San Diego, CA, USA. Abstract LB-2.
25. Nolan D, Hammond E, James I, McKinnon E & Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy 2003; 8:617-626.
26. Raidel SM, Haase C, Jansen NR, Russ RB, Sutliff RL, Velsor LW, Day BJ, Hoit BD, Samarel AM & Lewis W. Targeted myocardial transgenic expression of HIV TAT causes cardiomyopathy and mitochondrial damage. American Journal of Physiology. Heart & Circulatory Physiology 2002; 282:H1672-H1678.
27. Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, Druillennec S, Hoebeke J, Briand JP, Irinopoulou T, Daugas E, Susin SA, Cointe D, Xie ZH, Reed JC, Roques BP & Kroemer G. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Journal of Experimental Medicine 2000; 19:33-46.
28. Roumier T, Vieira HL, Castedo M, Ferri KF, Boya P, Andreau K, Druillennec S, Joza N, Penninger JM, Roques B & Kroemer G. The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway. Cell Death & Differentiation 2002; 9:1212-1219.
29. Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, Beckett B, Krammer PH, Sekaly RP & Badley AD. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome C, caspase cleavage and nuclear fragmentation. Cell Death & Differentiation 2002; 9:1172-1184.
30. Polla BS, Kantengwa S, Francois D, Salvioli S, Franceschi C, Marsac C & Cossarizza A. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury. Proceedings of the National Academy of Sciences, USA 1996; 93:6458-6463.
31. Li YY, Chen D, Watkins SC & Feldman AM. Mitochondrial abnormalities in tumor necrosis factor-alpha-induced heart failure are associated with impaired DNA repair activity. Circulation 2001; 104:2492-2497.
32. Neuman MG, Shear NH, Bellentani S & Tiribelli C. Role of cytokines in ethanol-induced cytotoxicity in vitro in HepG2 cells. Gastroenterology 1998; 115:157-166.
33. Pessayre D, Mansouri A, Haouzi D & Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biology & Toxicology 1999; 15:367-373.
34. Chitturi S & Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Seminars in Liver Disease 2001; 21:27-41.
35. Geng Y, Hansson GK & Holme E. Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circulation Research 1992; 71:1268-1276.
36. Cossarizza A, Mussini C, Mongiardo N, Borghi V, Sabbatini A, De Rienzo B & Franceschi C. Mitochondria alterations and dramatic tendency to apoptosis in peripheral blood lymphocytes during acute HIV syndrome. AIDS 1997; 11:19-26.
37. Cossarizza A, Ortolani C, Mussini C, Borghi V, Guaraldi G, Mongiardo N, Bellesia E, Franceschini MG, De Rienzo B & Franceschi C. Massive activation of immune cells with an intact T cell repertoire in acute HIV syndrome. Journal of Infectious Diseases 1995; 172:105-112.
38. Franco JM, Rubio A, Rey C, Leal M, Macias J, Pineda JA, Sanchez B, Sanchez-Quijano A, Nunez-Roldan A & Lissen E. Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. European Journal of Clinical Microbiology & Infectious Diseases 1999; 18:733-736.
39. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC & Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000; 95:3191-3198.
40. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J & Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. Journal of AIDS 2000; 25:312-321.
41. Domingo P, Veloso S, Montero F, Sirvent J, Matias-Guiu X, Vialdes J, Gutierrez C, Sambeat MA, Aguilar C, Peraire J, Richart C & Richart C. Serum levels of soluble tumor necrosis factor (TNF) receptors correlate with the degree of subcutaneous adipocyte apoptosis in HIV-infected patients with lipodystrophy. 14th AIDS International Conference. 7-12 July 2002, Barcelona, Spain. Abstract WePeA5792.
42. Johnson JA, Albu JB, Engelson ES, Fried SK, Inada Y, Ionescu G & Kotler DP. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. American Journal of Physiology, Endocrinology & Metabolism 2004; 286:E261-E271.
43. Lagathu C, Bastard JP, Auclair M, Maachi M, Kornprobst M, Capeau J & Caron M. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antiviral Therapy 2004; 9:911-920.
44. Christeff N, Melchior JC, de Truchis P, Perronne C & Gougeon ML. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. European Journal of Clinical Investigation 2002; 32:43-50.
45. Keilbaugh SA, Prusoff WH & Simpson VMV. The PC12 cell as a model for studies of mechanism of induction of peripheral neuropathy by anti-HIV dideoxynucleoside analogs. Biochemical Pharmacology 1991; 42:R5-R8.
46. Dalakas MC, Semino-Mora C & Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Laboratory Investigation 2001; 81:1537-1544.
47. Simpson DM & Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995; 9:153-161.
48. McCurdy DTr & Kennedy JM. AZT decreases rat myocardial cytochrome oxidase activity and increase beta-myosin heavy chain content. Journal of Molecular & Cellular Cardiology 1998; 30:1979-1989.
49. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B & Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. New England Journal of Medicine 1990; 322:1098-1105.
50. Pezeshkpour G, Illa I & Dalakas MC. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies. Human Pathology 1991; 22:1281-1288.
51. Simpson DM, Citak KA, Godfrey E, Godbold J & Wolfe DE. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology 1993; 43:971-976.
52. Dalakas MC, Leon-Mozon ME, Bernardini I, Gahl WA & Jay CA. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Annals of Neurology 1994; 35:482-487.
53. Semino-Mora MC, Leon-Monzon ME & Dalakas MC. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of zidovudine in vitro. Laboratory Investigation 1994; 71:102-112.
54. Semino-Mora MC, Leon-Monzon ME & Dalakas MC. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part II: treatment with L-carnitine improves AZT-induced changes and prevents further destruction. Laboratory Investigation 1994; 71:773-781.
55. Pereira LF, Oliveira MB & Carnieri EG. Mitochondrial sensitivity to zidovudine. Cell Biochemistry & function 1998; 16:173-181.
56. de la Asuncion JG, del Olmo ML, Sastre J, Millan A, Pellin A, Pallardo FV & Vina J. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. Journal of Clinical Investigation 1998; 102:4-9.
57. Sales SD, Hoggard PG, Sunderland D, Khoo S, Hart CA & Back DJ. Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicology & Applied Pharmacology 2001; 177:54-58.
58. McKee EE, Lynx MD, Susan-Resiga D, Bentley AT, D'Haenens JP, Cullen D & Ferguson M. Zidovudine inhibits thymidine phosphorylation: a novel site of potential toxicity in non-mitotic cells. Antiviral Therapy 2004; 9:L9.
59. Rylova SN, Albertioni F, Flygh G & Eriksson S. Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochemical Pharmacology 2005; 69:951-960.
60. Setzer B, Schlesier M, Thomas AK & Walker UA. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. Antiviral Therapy 2005; 10:327-334.
61. van der Valk M, Casula M, Weverlingz GJ, van Kuijk K, van Eck-Smit B, Hulsebosch HJ, Nieuwkerk P, van Eeden A, Brinkman K, Lange J, de Ronde A & Reiss P. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antiviral Therapy 2004; 9:385-393.